source
- FDA urges biosimilar makers to adopt alternatives to clinical efficacy trialsFDA's Office of Therapeutic Biologics and Biosimilars, led by director Sarah Yim, announced that the agency is working to help sponsors rely less on clinical efficacy studies when developing biosim…
- Biotech startups opt out of AI for drug discovery, say STATThe latest STAT AI Prognosis newsletter notes that a number of biotech startups are deliberately avoiding artificial intelligence in their drug discovery programs. These companies argue that AI ma…